Tobramycin

Results: 62



#Item
21Rationale for the EUCAST clinical breakpoints

Rationale for the EUCAST clinical breakpoints

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2009-12-12 17:14:34
22New Drugs 4 Bad Bugs (ND4BB) Cross-project communication & collaboration COMBACTE (Topic 1) - Enabling

New Drugs 4 Bad Bugs (ND4BB) Cross-project communication & collaboration COMBACTE (Topic 1) - Enabling

Add to Reading List

Source URL: www.imi.europa.eu

Language: English - Date: 2014-03-05 10:28:43
23Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: ahca.myflorida.com

Language: English - Date: 2014-07-24 07:34:00
24Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: www.fdhc.state.fl.us

Language: English - Date: 2014-07-24 07:34:00
25Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: www.fdhc.state.fl.us

Language: English - Date: 2014-07-24 10:34:39
26Below is a list of the JCIH Risk Indicators for Permanent Early Onset and/or Late Progressive Hearing Loss in Childhood:  Parent or caregiver concern* regarding hearing, speech, language or developmental delay.

Below is a list of the JCIH Risk Indicators for Permanent Early Onset and/or Late Progressive Hearing Loss in Childhood:  Parent or caregiver concern* regarding hearing, speech, language or developmental delay.

Add to Reading List

Source URL: dhhs.ne.gov

Language: English - Date: 2014-10-09 00:41:04
27Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Anti-Infective Drugs Advisory Committee Meeting September 5, 2012 Location: The FDA White Oak Campus, Building 31, The Great Roo

Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Anti-Infective Drugs Advisory Committee Meeting September 5, 2012 Location: The FDA White Oak Campus, Building 31, The Great Roo

Add to Reading List

Source URL: www.fda.gov

Language: English
28NDA[removed]S-015 Page 3 Zylet™  loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3%

NDA[removed]S-015 Page 3 Zylet™ loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3%

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-06-07 09:50:05
29rccm2010091478ci[removed]

rccm2010091478ci[removed]

Add to Reading List

Source URL: cfcenter.stanford.edu

Language: English - Date: 2011-06-06 12:40:44
30Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: www.ahca.myflorida.com

Language: English - Date: 2014-07-24 10:34:39